Samsung Bioepis report flags supply reliability as key US biosimilar market factor
XLV•XLV•XLV•XLV•Samsung Bioepis’ fourth-quarter 2026 US biosimilar market report said supply reliability rivals price as a purchasing consideration. It cited shortages or supply restrictions affecting up to a quarter or more of a wholesaler’s biosimilar portfolio on a given day.
Samsung Bioepis released its fourth-quarter 2026 US biosimilar market report, highlighting supply reliability as a purchasing consideration that rivals price. The report said up to a quarter or more of a wholesaler’s biosimilar portfolio faced shortages or supply restrictions on a given day.
Within five years of launch, biosimilars across key therapeutic classes averaged 55% market share, while average sales prices were down 54%. Bevacizumab and ranibizumab biosimilars sustained recovered average sales prices across the third and fourth quarters, bucking historical price erosion. As of September 2026, the US had approved 98 biosimilars, of which 75 had launched, representing 77% of approvals.
